Drugs · Entity Annotation Prototype (beta)

6articles mentioning drugs

10drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: b/tsDMARDs ×

b/tsDMARDs

This drug is selected. Its supporting articles are shown below.

b/tsDMARDs6

Articles mentioning b/tsDMARDs

6 articles · page 1 of 1

Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry

rmdopen · abstract · 2026-06-23 · 2 matching annotations

75.6%

rituximab abatacept TNFi IL-6Ri JAKi b/tsDMARDs b/tsDMARDs rheumatoid arthritis RA

…nt started a b/tsDMARD (abatacept: 242, IL-6Ri: 317, JAKi: 333, rituximab: 176, TNFi: 874). Compared with the wrist, all joints demonstra…

Impact of trial exclusion criteria on real-world comparative effectiveness of targeted therapies in rheumatoid arthritis: the FIRST Registry

rmdopen · abstract · 2026-05-18 · 2 matching annotations

87.0%

interleukin 6 inhibitors b/tsDMARDs tumour necrosis factor inhibitors b/tsDMARDs CTLA4-Ig Janus kinase (JAK) inhibitors rheumatoid arthritis

… The proportion ineligible differed by b/tsDMARDs, highest with interleukin 6 inhibitors (47.4%) and CTLA4-Ig (45.1%) and lowest with Janus kinase (JAK)…

Mortality incidence in spondyloarthritis: real-world evidence using the TriNetX Global Collaborative Network

rmdopen · abstract · 2026-03-13 · 2 matching annotations

83.5%

b/tsDMARDs axSpA PsA ankylosing spondylitis psoriatic arthritis arthropathic psoriasis

…ncreased mortality (axSpA HR 1.65; PsA HR 1.26). Treatment with b/tsDMARDs, particularly tumour necrosis factor (TNF) inhibitors, reduced …

Using ultrasound to define inflammatory and non-inflammatory phenotypes in difficult-to-treat psoriatic arthritis

rmdopen · abstract · 2025-08-14 · 2 matching annotations

78.9%

biological disease-modifying anti-rheumatic drugs b/tsDMARDs D2T-PsA psoriatic arthritis PIPsA nail psoriasis NIPsA

…ross-sectional study was conducted on PsA patients treated with biological disease-modifying anti-rheumatic drugs/targeted synthetic disease-modifying anti-rheumatic drugs (b/ts…

Effects of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcome domains in rheumatoid arthritis: a systematic review and network meta-analyses

rmdopen · abstract · 2026-06-24 · 1 matching annotations

79.6%

rituximab IL-6 inhibitors b/tsDMARDs b/tsDMARDs Janus kinase inhibitors Health Assessment Questionnaire rheumatoid arthritis RA RA-relevant inflammatory arthritis

…he surface under the cumulative ranking curve demonstrated that rituximab was overall ranked best among b/tsDMARDs. IL-6 inhibitors ranke…

Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry

rmdopen · abstract · 2026-01-16 · 1 matching annotations

79.1%

IL-6Ri b/tsDMARDs Health Assessment Questionnaire D2T RA rheumatoid arthritis FIRST registry b/tsDMARD

…2T RA by the scoring system, interleukin-6 receptor inhibitors (IL-6Ri) significantly reduced D2T RA progression (relative risk (RR): …